<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6599047</article-id><article-id pub-id-type="pmcid-ver">PMC6599047.1</article-id><article-id pub-id-type="pmcaid">6599047</article-id><article-id pub-id-type="pmcaiid">6599047</article-id><article-id pub-id-type="pmid">31253840</article-id><article-id pub-id-type="doi">10.1038/s41598-019-45795-8</article-id><article-id pub-id-type="publisher-id">45795</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Optimal composition and position of histidine-containing tags improves biodistribution of <sup>99m</sup>Tc-labeled DARPin G3</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4778-3909</contrib-id><name name-style="western"><surname>Vorobyeva</surname><given-names initials="A">Anzhelika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schulga</surname><given-names initials="A">Alexey</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Konovalova</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>G&#252;ler</surname><given-names initials="R">Rezan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9423-0541</contrib-id><name name-style="western"><surname>L&#246;fblom</surname><given-names initials="J">John</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sandstr&#246;m</surname><given-names initials="M">Mattias</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garousi</surname><given-names initials="J">Javad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chernov</surname><given-names initials="V">Vladimir</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bragina</surname><given-names initials="O">Olga</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6120-2683</contrib-id><name name-style="western"><surname>Orlova</surname><given-names initials="A">Anna</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6122-1734</contrib-id><name name-style="western"><surname>Tolmachev</surname><given-names initials="V">Vladimir</given-names></name><address><email>vladimir.tolmachev@igp.uu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deyev</surname><given-names initials="SM">Sergey M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Department of Immunology, Genetics and Pathology, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2192 9124</institution-id><institution-id institution-id-type="GRID">grid.4886.2</institution-id><institution>Molecular Immunology Laboratory, Shemyakin &amp; Ovchinnikov Institute of Bioorganic Chemistry, </institution><institution>Russian Academy of Sciences, </institution></institution-wrap>Moscow, Russia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121581746</institution-id><institution-id institution-id-type="GRID">grid.5037.1</institution-id><institution>Department of Protein Science, School of Engineering Sciences in Chemistry, </institution><institution>Biotechnology and Health, KTH Royal Institute of Technology, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Nuclear Medicine and PET, Department of Surgical Sciences, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.473330.0</institution-id><institution>Nuclear Medicine Department, Cancer Research Institute, </institution><institution>Tomsk National Research Medical Center Russian Academy of Sciences, </institution></institution-wrap>Tomsk, Russia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Department of Medicinal Chemistry, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution>Science for Life Laboratory, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9321 1499</institution-id><institution-id institution-id-type="GRID">grid.27736.37</institution-id><institution>National Research Tomsk Polytechnic University, </institution></institution-wrap>Tomsk, Russia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8868 5198</institution-id><institution-id institution-id-type="GRID">grid.183446.c</institution-id><institution>Bio-Nanophotonic Lab, Institute of Engineering Physics for Biomedicine (PhysBio), </institution><institution>National Research Nuclear University &#8220;MEPhI&#8221;, </institution></institution-wrap>Moscow, Russia </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">327256</issue-id><elocation-id>9405</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>06</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>10</day><month>07</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-07-11 00:14:44.337"><day>11</day><month>07</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2019_Article_45795.pdf"/><abstract id="Abs1"><p id="Par1">Radionuclide molecular imaging of HER2 expression in disseminated cancer enables stratification of patients for HER2-targeted therapies. DARPin G3, a small (14&#8201;kDa) engineered scaffold protein, is a promising probe for imaging of HER2. We hypothesized that position (C- or N-terminus) and composition (hexahistidine or (HE)<sub>3</sub>) of histidine-containing tags would influence the biodistribution of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-labeled DARPin G3. To test the hypothesis, G3 variants containing tags at N-terminus (H<sub>6</sub>-G3 and (HE)<sub>3</sub>-G3) or at C-terminus (G3-H<sub>6</sub> and G3-(HE)<sub>3</sub>) were labeled with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>. Labeling yield, label stability, specificity and affinity of the binding to HER2, biodistribution and tumor targeting properties of these variants were compared side-by-side. There was no substantial influence of position and composition of the tags on binding of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-labeled variants to HER2. The specificity of HER2 targeting <italic toggle="yes">in vivo</italic> was confirmed. The tumor uptake in BALB/c nu/nu mice bearing SKOV3 xenografts was similar for all variants. On the opposite, there was a strong influence of the tags on uptake in normal tissues. The tumor-to-liver ratio for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 was three-fold higher compared to the hexahistidine-tag containing variants. Overall, [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 variant provided the highest tumor-to-lung, tumor-to-liver, tumor-to-bone and tumor-to-muscle ratios, which should improve sensitivity of HER2 imaging in these common metastatic sites.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Predictive markers</kwd><kwd>Cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsr&amp;amp;#x00E5;det (Swedish Research Council)</institution></institution-wrap></funding-source><award-id>2015-02353</award-id><award-id>2015-02353</award-id><principal-award-recipient><name name-style="western"><surname>Orlova</surname><given-names>Anna</given-names></name><name name-style="western"><surname>Tolmachev</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002794</institution-id><institution>Cancerfonden (Swedish Cancer Society)</institution></institution-wrap></funding-source><award-id>2017/425</award-id><award-id>2018/436</award-id><principal-award-recipient><name name-style="western"><surname>Orlova</surname><given-names>Anna</given-names></name><name name-style="western"><surname>Tolmachev</surname><given-names>Vladimir</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Current and further progress in efficient treatment of disseminated cancer is often linked with molecular recognition of receptors, which are aberrantly expressed in malignant cells and maintain such hallmarks of cancer as sustained proliferative signaling, active invasiveness, angiogenesis induction, and apoptosis resistance. These receptors can be used as molecular targets for signaling inhibition or delivery of cytotoxic drugs. One such target is the human epidermal growth factor receptor (HER2). Treatment of patients with HER2-positive breast and advanced gastric or gastro-esophageal junction cancers with specific antibodies or tyrosine kinase inhibitors provides significant survival of patients<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. In both cases, high HER2 expression is a predictive biomarker for response to therapy and patients are routinely screened by analysis of biopsy samples. However, an appreciable inter- and intratumoral heterogeneity<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> of HER2 expression makes this method unreliable. Radionuclide imaging of HER2 is considered a promising way to overcome the problem of heterogeneity of HER2 expression and has the potential to improve precision of cancer treatments<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. It has been demonstrated in clinical trials that imaging of HER2 expression in tumors using radiolabeled monoclonal anti-HER2 antibody trastuzumab can predict response to treatment with trastuzumab<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> and the antibody-drug conjugate trastuzumab-DM1<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par3">Although the use of radiolabeled monoclonal antibodies is straightforward, it is associated with long time (4&#8211;6 days) between injection and imaging<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and with a risk of false-positive findings due to non-target-specific accumulation in tumors because of the &#8220;enhanced permeability and retention&#8221; (EPR) effect<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Reduction in size of a protein-based imaging probe increases imaging contrast, reduces optimal time between injection and imaging, and minimizes the EPR effect<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Therefore, appreciable efforts are invested in development of imaging probes that are smaller than immunoglobulins<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par4">One of the possible approaches for the development of small targeting protein probes for imaging is the use of engineered scaffold proteins (ESP)<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. ESPs have variable amino acids incorporated in a structurally rigid core (scaffold). Randomization of variable amino acids enables selection of binders to different molecular target, and the presence of the core minimizes entropy penalty and ensures high binding affinity. One promising class of ESP for molecular imaging are designed ankyrin repeat proteins (DARPins). The DARPin scaffold is built from three or four 33-amino acid-repeats containing a &#946;-turn and two anti-parallel &#945;-helices<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1A</xref>). DARPins typically have high thermodynamic stability against thermal and chemical denaturation, and high solubility<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Another potential advantage of DARPins is the highly efficient production in prokaryotic hosts, which reduces manufacturing costs<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. High-affinity DARPin-based binders to different molecular targets have been selected for applications in, for example, basic biology research, biosensors, and tumor targeting. Particularly, selection of two DARPins with high affinity to HER2, 9_29 (3.8&#8201;nM)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and G3 (0.09&#8201;nM)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, has been reported. Feasibility of radionuclide targeting of HER2 using G3 having a hexahistidine tag at N-terminus (H<sub>6</sub>-G3) and labeled with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> has been demonstrated<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. However, [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 provided a quite low tumor-to-liver ratio (1.1) at 4&#8201;h after injection. This would prevent imaging of hepatic metastases, which are frequent in many cancers, including breast carcinoma. Tumor-to-liver ratio for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-9_29 DARPin was even lower, 0.11&#8201;&#177;&#8201;0.02 at 6&#8201;h after injection<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. It is highly likely that the elevated hepatic uptake was associated with the unfavorable combination of the hexahistidine tag<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup> and high lipophilicity of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>. The use of the more hydrophilic chelator DOTA with the radionuclide <sup>111</sup>In and removal of the hexahistidine tag appreciably reduced the hepatic uptake of [<sup>111</sup>In]In-DOTA-G3 and increased the tumor-to-liver ratio up to 12&#8201;&#177;&#8201;2<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Schematic illustration of proteins used as targeting vehicles for molecular imaging. (<bold>A</bold>) Structures of an IgG monoclonal antibody sized relative to a DARPin G3. (<bold>B</bold>) Four DARPin G3 variants having histidine-containing tags at N-terminus or C-terminus were used in this study. Illustrations were taken from Research Collaboratory for Structural Bioinformatics Protein Data Bank: 1IGT (antibody), 2JAB (DARPin).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e602" position="float" orientation="portrait" xlink:href="41598_2019_45795_Fig1_HTML.jpg"/></fig></p><p id="Par5">Another approach to increase the tumor-to-liver ratio for radiolabeled DARPins was based on the use of non-residualizing labels, i.e. labels that &#8220;leak&#8221; from tumors after internalization and lysosomal degradation<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Usually, the use of residualizing labels is necessary for rapidly internalized peptides<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, although such labels are also trapped in normal tissues and retained there. It was found that internalization of G3 DARPin after binding to cancer cells was slow<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Thus, the use of a residualizing radiometal label is not mandatory. In fact, the use of non-residualizing radioiodine label did not cause reduction of tumor uptake of G3 in comparison with the use of the residualizing [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> label but resulted in a substantial reduction of hepatic uptake, providing excellent tumor-to-liver ratio, 11&#8201;&#177;&#8201;2 at 6&#8201;h after injection<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Furthermore, direct electrophilic radioiodination was found to be a better labeling approach for G3 compared to indirect radioiodination using HPEM<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par6">A high imaging contrast (i.e. high tumor-to-organ ratios) is the primary goal in the development of imaging probes. Nonetheless, imaging properties of a radionuclide label and economic aspects should also be taken into account to facilitate rapid clinical translation. Indium-111 (t<sub>1/2</sub>&#8201;=&#8201;2.8 d) provided good tumor-to-organ ratios for G3 DARPin in animal studies. However, this nuclide emits an abundant gamma quantum with the energy of 245&#8201;keV. Imaging using <sup>111</sup>In requires the use of a medium energy general purpose collimator, which reduces both resolution and sensitivity of imaging compared to the low energy high resolution collimator suitable for <sup>123</sup>I and <sup>99m</sup>Tc. Besides, this nuclide is quite expensive. The use of <sup>123</sup>I (t<sub>1/2</sub>&#8201;=&#8201;13.7&#8201;h) for single photon computed tomography (SPECT) imaging or <sup>124</sup>I (t<sub>1/2</sub>&#8201;=&#8201;4.18 d), for positron emission tomography (PET) imaging would provide appreciably better resolution and sensitivity compared with the use of <sup>111</sup>In, though, the costs of the radionuclides would be high as well. The generator-produced <sup>99m</sup>Tc (t<sub>1/2</sub>&#8201;=&#8201;6&#8201;h) is by orders of magnitude cheaper compared to iodine isotopes. The cost, in combination with excellent availability and favorable dosimetry, makes it a highly attractive label for SPECT applications. Therefore, development of a technetium-based label with optimal biodistribution properties for DARPins is desirable.</p><p id="Par7">Studies on affibody molecules have showed that substitution of a hexahistidine tag by a histidine-glutamate-histidine-glutamate-histidine-glutamate (HEHEHE or (HE)<sub>3</sub>) tag permitted both immobilized metal ion affinity chromatography (IMAC) purification and site-specific labeling with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub><sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. At the same time, the use of this tag reduced hepatic uptake of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-labeled anti-HER2 affibody molecules more than 10-fold compared with counterpart molecules containing hexahistidine tag<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Interestingly, the effect of a histidine-containing tag on hepatic uptake of affibody molecules was dependent on its position in the protein and the effect was much more pronounced in the case of N-terminal placement compared with the placement at C-terminus<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. However, the influence of the tag on biodistribution is different for various types of ESPs. For example, the effect of a (HE)<sub>3</sub>-tag on biodistribution of another ESP, ADAPT, was minor<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par8">The goal of this study was to test the hypothesis that position (C- or N-terminus) and composition (hexahistidine or (HE)<sub>3</sub>) of histidine-containing tags would influence the biodistribution of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-labeled anti-HER2 DARPin G3. To test the hypothesis, G3 variants containing tags at N-terminus (H<sub>6</sub>-G3 and (HE)<sub>3</sub>-G3) or C-terminus (G3-H<sub>6</sub> and G3-(HE)<sub>3</sub>) were labeled with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1B</xref>). Binding to HER2 <italic toggle="yes">in vitro</italic>, biodistribution and tumor targeting properties of these variants were studied side-by-side.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Labeling and stability</title><p id="Par9">The identity of non-labeled DARPin G3 variants was confirmed using mass spectrometry analysis (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>). All G3 variants were successfully labeled with tricarbonyl technetium. Incubation of G3 variants with tricarbonyl technetium complex for 60&#8201;min at 60&#8201;&#176;C provided radiochemical yield over 50% (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Purification using NAP-5 size-exclusion columns provided radiochemical purities over 97%. The radiocolloid content was in the range of 0.6&#8211;1.6%. Radio-HPLC analysis of <sup>99m</sup>Tc-labeled G3 variants after purification showed a single peak for all proteins (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Radiochemical yield, isolated yield, radiochemical purity and maximum apparent specific activity of <sup>99m</sup>Tc-labeled G3 variants. Experiments were performed in duplicates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Conjugate</th><th colspan="1" rowspan="1">Radiochemical yield, %*</th><th colspan="1" rowspan="1">Isolated yield, %*</th><th colspan="1" rowspan="1">Radiochemical purity, %</th><th colspan="1" rowspan="1">Maximum specific activity, MBq/&#956;g (GBq/&#956;mol)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3</td><td colspan="1" rowspan="1">87&#8201;&#177;&#8201;6</td><td colspan="1" rowspan="1">72&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">2.8 (40.1)</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub></td><td colspan="1" rowspan="1">58&#8201;&#177;&#8201;4</td><td colspan="1" rowspan="1">50&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">3.0 (42.9)</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3</td><td colspan="1" rowspan="1">72&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">68&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">3.1 (44.4)</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub></td><td colspan="1" rowspan="1">66&#8201;&#177;&#8201;5</td><td colspan="1" rowspan="1">57&#8201;&#177;&#8201;4</td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">3.4 (48.6)</td></tr></tbody></table><table-wrap-foot><p>*Radiochemical yield is based on iTLC analysis of the crude product;</p><p>Isolated yield is defined as a percentage of activity in the high molecular weight fraction after size-exclusion chromatography purification in total activity (leftover in the reaction vial, activity in a column, and activity in the high molecular weight fraction).</p></table-wrap-foot></table-wrap></p><p id="Par10">All radiolabeled G3 variants demonstrated high stability after incubation with 5000-fold molar excess of histidine up to 3&#8201;h (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p><italic toggle="yes">In vitro</italic> stability of <sup>99m</sup>Tc-labeled G3 variants. Samples were incubated with 5000-fold molar excess of histidine or in PBS. Experiments were performed in duplicates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Conjugate</th><th colspan="2" rowspan="1">1&#8201;h</th><th colspan="2" rowspan="1">3&#8201;h</th></tr><tr><th colspan="1" rowspan="1">PBS</th><th colspan="1" rowspan="1">5000x histidine</th><th colspan="1" rowspan="1">PBS</th><th colspan="1" rowspan="1">5000x histidine</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub></td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3</td><td colspan="1" rowspan="1">99&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">97&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub></td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">98&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">97&#8201;&#177;&#8201;0</td><td colspan="1" rowspan="1">97&#8201;&#177;&#8201;0</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title><italic toggle="yes">In vitro</italic> binding specificity and processing by cells</title><p id="Par11">The binding of all radiolabeled G3 variants to cells with high (SKOV3, BT474) and low (DU145) HER2 expression was significantly (p&#8201;&lt;&#8201;0.01) reduced in the presence of a large excess of the corresponding non-labeled DARPin G3 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The results of the binding specificity experiment showed that the binding was HER2-mediated and radiolabeling did not have a negative influence on binding specificity.</p><p id="Par12">The binding kinetics of radiolabeled G3 variants to living SKOV3 cells was determined using LigandTracer. The binding and dissociation data were best fitted to the one-to-two Langmuir binding model. As it was previously observed for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>]-G3-H<sub>6</sub><sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, all variants had a high affinity interaction in the picomolar range and a low affinity one in the nanomolar range (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Equilibrium dissociation constants (K<sub><italic toggle="yes">D</italic></sub>) for the interactions between [<sup>99m</sup>Tc]Tc-labeled G3 variants and HER2-expressing SKOV3 cells. Experiments were performed in duplicates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Conjugate</th><th colspan="1" rowspan="1">K<sub><italic toggle="yes">D1</italic></sub> (pM)</th><th colspan="1" rowspan="1">K<sub><italic toggle="yes">D2</italic></sub> (nM)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3</td><td colspan="1" rowspan="1">90&#8201;&#177;&#8201;5</td><td colspan="1" rowspan="1">3.3&#8201;&#177;&#8201;0.2</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub></td><td colspan="1" rowspan="1">118&#8201;&#177;&#8201;38</td><td colspan="1" rowspan="1">2.5&#8201;&#177;&#8201;1.5</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3</td><td colspan="1" rowspan="1">96&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">1.2&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub></td><td colspan="1" rowspan="1">89&#8201;&#177;&#8201;11</td><td colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;0.5</td></tr></tbody></table></table-wrap></p><p id="Par13">Cellular processing of <sup>99m</sup>Tc-labeled G3 variants by HER2-expressing SKOV3 cells during continuous incubation is presented in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>. All variants showed a similar pattern of processing with rapid binding to cells and relatively slow internalization. However, some differences between constructs with H<sub>6</sub> and (HE)<sub>3</sub> were observed. There was significant (p&#8201;&lt;&#8201;0.005) increase of cell-associated activity between 6 and 24&#8201;h for hexahistidine-tag-containing DARPins, but not for the (HE)<sub>3</sub>-containing ones. The internalized fraction at 24&#8201;h was higher (significant difference in ANOVA analysis with Bonferroni correction for multiple comparisons) for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> (37.0&#8201;&#177;&#8201;1.5% and 33.2&#8201;&#177;&#8201;1.5%, respectively) than for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub> (26.7&#8201;&#177;&#8201;0.7% and 25.5&#8201;&#177;&#8201;1.5%, respectively). However, the difference was not significant at earlier time points.</p></sec><sec id="Sec5"><title>Biodistribution studies</title><p id="Par14">The specificity of HER2-targeting by <sup>99m</sup>Tc-labeled G3 variants was confirmed in BALB/c nun/nu mice <italic toggle="yes">in vivo</italic>. The tumor uptake in HER2-negative Ramos xenografts was significantly (p&#8201;&lt;&#8201;0.05, unpaired t test) lower than in HER2-positive SKOV3 xenografts (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par15">Side-by-side comparison of biodistribution of four radiolabeled G3 variants in BALB/c nu/nu mice bearing SKOV3 xenografts is shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. All four variants provided similar tumor uptake (7&#8211;9%ID/g) at 4&#8201;h pi (p&#8201;&gt;&#8201;0.05, one-way ANOVA test) and had good retention in tumors up to 24&#8201;h pi with no significant (p&#8201;&gt;&#8201;0.05, one-way ANOVA test) difference between variants, except for a minor decrease for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. All variants demonstrated predominantly renal clearance. The liver uptake of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 was three-fold lower than of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and about two-fold lower than of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> or of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. Additionally, the G3 variant with N-terminal (HE)<sub>3</sub>-tag had the lowest uptake of all four variants in lungs, spleen, and muscle at 4&#8201;h pi and in liver, spleen and stomach at 24&#8201;h pi (p&#8201;&lt;&#8201;0.05, one-way ANOVA test). As a result, it provided the highest tumor-to-organ ratios of all four variants for salivary glands, liver, spleen, stomach and muscles at both 4&#8201;h and 24&#8201;h pi (p&#8201;&lt;&#8201;0.05, one-way ANOVA test) (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Comparative biodistribution of <sup>99m</sup>Tc-labeled G3 variants in BALB/C nu/nu mice bearing SKOV3 xenografts at 4 and 24&#8201;h pi.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3</th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub></th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3</th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub></th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><bold>4</bold>&#8201;<bold>h</bold></td></tr><tr><td colspan="1" rowspan="1">Blood</td><td colspan="1" rowspan="1">0.19&#8201;&#177;&#8201;0.06<sup>c</sup></td><td colspan="1" rowspan="1">0.14&#8201;&#177;&#8201;0.03<sup>e</sup></td><td colspan="1" rowspan="1">0.18&#8201;&#177;&#8201;0.03<sup>f</sup></td><td colspan="1" rowspan="1">0.36&#8201;&#177;&#8201;0.07</td></tr><tr><td colspan="1" rowspan="1">Salivary glands</td><td colspan="1" rowspan="1">1.9&#8201;&#177;&#8201;0.2<sup>c</sup></td><td colspan="1" rowspan="1">1.5&#8201;&#177;&#8201;0.2</td><td colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.2<sup>b,d</sup></td><td colspan="1" rowspan="1">1. 1&#8201;&#177;&#8201;0.3</td></tr><tr><td colspan="1" rowspan="1">Lung</td><td colspan="1" rowspan="1">0.5&#8201;&#177;&#8201;0.1<sup>a</sup></td><td colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.34&#8201;&#177;&#8201;0.02<sup>b,d,f</sup></td><td colspan="1" rowspan="1">0.6&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">5.5&#8201;&#177;&#8201;0.3<sup>c</sup></td><td colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;0.9</td><td colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;0.1<sup>b,d,f</sup></td><td colspan="1" rowspan="1">3.1&#8201;&#177;&#8201;0.7</td></tr><tr><td colspan="1" rowspan="1">Spleen</td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.1<sup>a</sup></td><td colspan="1" rowspan="1">1.1&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.47&#8201;&#177;&#8201;0.04<sup>b,d,f</sup></td><td colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Stomach</td><td colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.2</td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1<sup>b,d</sup></td><td colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Kidney</td><td colspan="1" rowspan="1">297&#8201;&#177;&#8201;16<sup>a,c</sup></td><td colspan="1" rowspan="1">220&#8201;&#177;&#8201;30</td><td colspan="1" rowspan="1">237&#8201;&#177;&#8201;30</td><td colspan="1" rowspan="1">211&#8201;&#177;&#8201;41</td></tr><tr><td colspan="1" rowspan="1">Tumor</td><td colspan="1" rowspan="1">9&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">8&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">9&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">7&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">Muscle</td><td colspan="1" rowspan="1">0.21&#8201;&#177;&#8201;0.03</td><td colspan="1" rowspan="1">0.3&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.11&#8201;&#177;&#8201;0.01<sup>b,d,f</sup></td><td colspan="1" rowspan="1">0.23&#8201;&#177;&#8201;0.04</td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.3</td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1<sup>b,d</sup></td><td colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.2</td></tr><tr><td colspan="5" rowspan="1"><bold>24</bold>&#8201;<bold>h</bold></td></tr><tr><td colspan="1" rowspan="1">Blood</td><td colspan="1" rowspan="1">0.07&#8201;&#177;&#8201;0.01<sup>c</sup></td><td colspan="1" rowspan="1">0.08&#8201;&#177;&#8201;0.01<sup>e</sup></td><td colspan="1" rowspan="1">0.09&#8201;&#177;&#8201;0.01<sup>f</sup></td><td colspan="1" rowspan="1">0.15&#8201;&#177;&#8201;0.01</td></tr><tr><td colspan="1" rowspan="1">Salivary glands</td><td colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.3</td><td colspan="1" rowspan="1">1.5&#8201;&#177;&#8201;0.2<sup>e</sup></td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1<sup>d</sup></td><td colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.2</td></tr><tr><td colspan="1" rowspan="1">Lung</td><td colspan="1" rowspan="1">0.3&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.7&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.3&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">3.6&#8201;&#177;&#8201;0.4<sup>a,c</sup></td><td colspan="1" rowspan="1">4.6&#8201;&#177;&#8201;0.4</td><td colspan="1" rowspan="1">1.2&#8201;&#177;&#8201;0.2<sup>b,d,f</sup></td><td colspan="1" rowspan="1">2.6&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Spleen</td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.4</td><td colspan="1" rowspan="1">1.1&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1<sup>b,d,f</sup></td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="1" rowspan="1">Stomach</td><td colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.1</td><td colspan="1" rowspan="1">0.22&#8201;&#177;&#8201;0.04<sup>b,d,f</sup></td><td colspan="1" rowspan="1">0.40&#8201;&#177;&#8201;0.03</td></tr><tr><td colspan="1" rowspan="1">Kidney</td><td colspan="1" rowspan="1">177&#8201;&#177;&#8201;25</td><td colspan="1" rowspan="1">212&#8201;&#177;&#8201;31</td><td colspan="1" rowspan="1">134&#8201;&#177;&#8201;16<sup>b</sup></td><td colspan="1" rowspan="1">144&#8201;&#177;&#8201;7</td></tr><tr><td colspan="1" rowspan="1">Tumor</td><td colspan="1" rowspan="1">8&#8201;&#177;&#8201;2<sup>c</sup></td><td colspan="1" rowspan="1">9&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">7&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">5&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">Muscle</td><td colspan="1" rowspan="1">0.16&#8201;&#177;&#8201;0.02</td><td colspan="1" rowspan="1">0.31&#8201;&#177;&#8201;0.04</td><td colspan="1" rowspan="1">0.08&#8201;&#177;&#8201;0.02<sup>d,f</sup></td><td colspan="1" rowspan="1">0.20&#8201;&#177;&#8201;0.04</td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">0.5&#8201;&#177;&#8201;0.1<sup>c</sup></td><td colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.3</td><td colspan="1" rowspan="1">0.3&#8201;&#177;&#8201;0.1<sup>d,f</sup></td><td colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.1</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean %ID/g values with SD from four mice. One-way ANOVA with Bonferroni&#8217;s multiple comparisons test was performed to find significant differences. <sup>a</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub>. <sup>b</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. <sup>c</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. <sup>d</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. <sup>e</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. <sup>f</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>.</p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Tumor-to-organ ratios for <sup>99m</sup>Tc-labeled G3 variants in BALB/C nu/nu mice bearing SKOV3 xenografts at 4 and 24&#8201;h pi.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3</th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub></th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3</th><th colspan="1" rowspan="1">[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub></th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><bold>4</bold>&#8201;<bold>h</bold></td></tr><tr><td colspan="1" rowspan="1">Blood</td><td colspan="1" rowspan="1">46&#8201;&#177;&#8201;20<sup>c</sup></td><td colspan="1" rowspan="1">54&#8201;&#177;&#8201;7<sup>e</sup></td><td colspan="1" rowspan="1">49&#8201;&#177;&#8201;10<sup>f</sup></td><td colspan="1" rowspan="1">19&#8201;&#177;&#8201;2</td></tr><tr><td colspan="1" rowspan="1">Salivary glands</td><td colspan="1" rowspan="1">5&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">5&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">13&#8201;&#177;&#8201;4<sup>b,d,f</sup></td><td colspan="1" rowspan="1">6&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">Lung</td><td colspan="1" rowspan="1">18&#8201;&#177;&#8201;7</td><td colspan="1" rowspan="1">11&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">26&#8201;&#177;&#8201;3<sup>d,f</sup></td><td colspan="1" rowspan="1">12&#8201;&#177;&#8201;2</td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">1.6&#8201;&#177;&#8201;0.7</td><td colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;0.3</td><td colspan="1" rowspan="1">4.9&#8201;&#177;&#8201;0.3<sup>b,d,f</sup></td><td colspan="1" rowspan="1">2.2&#8201;&#177;&#8201;0.3</td></tr><tr><td colspan="1" rowspan="1">Spleen</td><td colspan="1" rowspan="1">10&#8201;&#177;&#8201;4</td><td colspan="1" rowspan="1">7&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">19&#8201;&#177;&#8201;2<sup>b,d,f</sup></td><td colspan="1" rowspan="1">7&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">Stomach</td><td colspan="1" rowspan="1">12&#8201;&#177;&#8201;5</td><td colspan="1" rowspan="1">9&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">23&#8201;&#177;&#8201;6<sup>b,d,f</sup></td><td colspan="1" rowspan="1">10.2&#8201;&#177;&#8201;0.2</td></tr><tr><td colspan="1" rowspan="1">Kidney</td><td colspan="1" rowspan="1">0.03&#8201;&#177;&#8201;0.01</td><td colspan="1" rowspan="1">0.04&#8201;&#177;&#8201;0.01</td><td colspan="1" rowspan="1">0.037&#8201;&#177;&#8201;0.004</td><td colspan="1" rowspan="1">0.03&#8201;&#177;&#8201;0.01</td></tr><tr><td colspan="1" rowspan="1">Muscle</td><td colspan="1" rowspan="1">42&#8201;&#177;&#8201;20</td><td colspan="1" rowspan="1">26&#8201;&#177;&#8201;6</td><td colspan="1" rowspan="1">80&#8201;&#177;&#8201;5<sup>b,d,f</sup></td><td colspan="1" rowspan="1">29&#8201;&#177;&#8201;4</td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">10&#8201;&#177;&#8201;4</td><td colspan="1" rowspan="1">9&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">25&#8201;&#177;&#8201;4<sup>b,d,f</sup></td><td colspan="1" rowspan="1">10&#8201;&#177;&#8201;2</td></tr><tr><td colspan="5" rowspan="1"><bold>24</bold>&#8201;<bold>h</bold></td></tr><tr><td colspan="1" rowspan="1">Blood</td><td colspan="1" rowspan="1">110&#8201;&#177;&#8201;12<sup>a,c</sup></td><td colspan="1" rowspan="1">83&#8201;&#177;&#8201;11<sup>e</sup></td><td colspan="1" rowspan="1">80&#8201;&#177;&#8201;6<sup>b,f</sup></td><td colspan="1" rowspan="1">32&#8201;&#177;&#8201;7</td></tr><tr><td colspan="1" rowspan="1">Salivary glands</td><td colspan="1" rowspan="1">8&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">4&#8201;&#177;&#8201;2</td><td colspan="1" rowspan="1">16&#8201;&#177;&#8201;3<sup>b,d,f</sup></td><td colspan="1" rowspan="1">6&#8201;&#177;&#8201;1</td></tr><tr><td colspan="1" rowspan="1">Lung</td><td colspan="1" rowspan="1">25&#8201;&#177;&#8201;5<sup>a,c</sup></td><td colspan="1" rowspan="1">17&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">28&#8201;&#177;&#8201;2<sup>d,f</sup></td><td colspan="1" rowspan="1">12&#8201;&#177;&#8201;2</td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">2.3&#8201;&#177;&#8201;0.6</td><td colspan="1" rowspan="1">2.3&#8201;&#177;&#8201;0.6</td><td colspan="1" rowspan="1">5.9&#8201;&#177;&#8201;0.9<sup>b,d,f</sup></td><td colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;0.4</td></tr><tr><td colspan="1" rowspan="1">Spleen</td><td colspan="1" rowspan="1">10&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">8&#8201;&#177;&#8201;1</td><td colspan="1" rowspan="1">20&#8201;&#177;&#8201;3<sup>b,d,f</sup></td><td colspan="1" rowspan="1">6&#8201;&#177;&#8201;2</td></tr><tr><td colspan="1" rowspan="1">Stomach</td><td colspan="1" rowspan="1">21&#8201;&#177;&#8201;4</td><td colspan="1" rowspan="1">12&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">32&#8201;&#177;&#8201;7<sup>b,d,f</sup></td><td colspan="1" rowspan="1">12&#8201;&#177;&#8201;3</td></tr><tr><td colspan="1" rowspan="1">Kidney</td><td colspan="1" rowspan="1">0.045&#8201;&#177;&#8201;0.002</td><td colspan="1" rowspan="1">0.04&#8201;&#177;&#8201;0.01</td><td colspan="1" rowspan="1">0.05&#8201;&#177;&#8201;0.01<sup>f</sup></td><td colspan="1" rowspan="1">0.03&#8201;&#177;&#8201;0.01</td></tr><tr><td colspan="1" rowspan="1">Muscle</td><td colspan="1" rowspan="1">51&#8201;&#177;&#8201;16<sup>c</sup></td><td colspan="1" rowspan="1">30&#8201;&#177;&#8201;15</td><td colspan="1" rowspan="1">84&#8201;&#177;&#8201;5<sup>b,d,f</sup></td><td colspan="1" rowspan="1">24&#8201;&#177;&#8201;7</td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">16&#8201;&#177;&#8201;3</td><td colspan="1" rowspan="1">11&#8201;&#177;&#8201;5</td><td colspan="1" rowspan="1">24&#8201;&#177;&#8201;10<sup>d,f</sup></td><td colspan="1" rowspan="1">6&#8201;&#177;&#8201;2</td></tr></tbody></table><table-wrap-foot><p>One-way ANOVA with Bonferroni&#8217;s multiple comparisons test was performed to find significant differences. <sup>a</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub>. <sup>b</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. <sup>c</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-H<sub>6</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. <sup>d</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. <sup>e</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-H<sub>6</sub> and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>. <sup>f</sup>Significant difference between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 and [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-G3-(HE)<sub>3</sub>.</p></table-wrap-foot></table-wrap></p><p id="Par16">Experimental gamma-camera imaging confirmed the biodistribution results. The SKOV3 xenografts were visualized using all <sup>99m</sup>Tc-labeled G3 variants (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). However, the background activity was the lowest in the case of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. Particularly, the activity accumulation in liver was noticeably lower compared to other variants.</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par17">Clinical radionuclide molecular imaging utilizes two major modalities, PET and SPECT. Until very recently, there was a consensus that SPECT is appreciably cheaper and more available, while PET provides better spatial resolution, sensitivity and quantitation accuracy<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Accordingly, the focus in development of radiolabeled antibodies and peptides was shifted to the use of positron-emitting radionuclides during the last decade<sup><xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref></sup>. Introduction of new semiconductor cadmium zinc telluride (CZT) detectors for whole body SPECT/CT has changed the situation dramatically. The spatial resolution of CZT-SPECT was improved two-fold compared with conventional Anger-camera based SPECT<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, which enhanced the sensitivity of imaging due to lower partial volume effect. In addition, the use of CT-based attenuation correction has appreciably improved the quantitation accuracy of CZT-SPECT. The performance of CZT-SPECT in static imaging is approaching the performance of PET, but at appreciably lower price. It makes sense again to develop imaging probes for SPECT. The development of cheap <sup>99m</sup>Tc-based imaging probes would further promote CZT-SPECT imaging.</p><p id="Par18">The use of histidine-based tags as chelators for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> offers several advantages<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. They simplify purification of recombinant proteins using IMAC. They are incorporated into the protein by genetic engineering, and thus avoid the need for chelator conjugation and purification, which reduces production costs. Furthermore, histidine tags enable site-specific coupling of the radionuclide, which minimizes the risk of undesirable modification of amino acids in the binding site of a scaffold protein and provides a uniform labeled product with reproducible biodistribution properties.</p><p id="Par19">We have selected the G3 DARPin for optimization in this study, because it demonstrated appreciably better imaging properties with both <sup>99m</sup>Tc and <sup>125</sup>I labels compared with 9_29 DARPin<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Four G3 variants containing a histidine-containing tag at either N-terminus (H<sub>6</sub>-G3 and (HE)<sub>3</sub>-G3) or C-terminus (G3-H<sub>6</sub> and G3-(HE)<sub>3</sub>) were generated. Labeling of all variants with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> using CRS kit was quite efficient, stable and provided high radiochemical purity after purification by size-exclusion chromatography (Tables&#160;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>). All labeled variants preserved specific binding to HER2-expressing cells <italic toggle="yes">in vitro</italic> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and had similar affinity to living HER2-expressing cells (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The cellular processing of all labeled variants had a similar pattern with rather slow internalization (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The internalized activity at 24&#8201;h was somewhat higher in the case of hexahistidine-containing variants, which might indicate somewhat stronger residualizing properties in this case. All radiolabeled variants demonstrated much higher accumulation in HER2-positive SKOV3 xenografts than in HER2-negative Ramos xenografts (p&#8201;&lt;&#8201;0.005) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>), which clearly demonstrated HER2-specificity of targeting <italic toggle="yes">in vivo</italic>. There was no significant difference between the tumor uptake of different G3 variants at 4&#8201;h after injection. The major finding of this study was the difference of uptake in normal tissues (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). Particularly, the uptake of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 in a majority of normal tissues was significantly lower compared to the three other variants (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). The influence of the tag composition was more pronounced for placement of the tag at the N-terminus. Accordingly, there was a significant difference in tumor-to-organ ratio between [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 and other radiolabeled variants (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). Importantly, [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 provided significantly higher tumor-to-liver, tumor-to-muscle and tumor-to-bone ratios, facilitating contrast at sites where metastases are frequently located. Data for radioiodinated G3<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> showed that tumor-to-blood, tumor-to-salivary gland, tumor-to-lung and tumor-to-muscle ratios increased at 24&#8201;h compared to 6&#8201;h, and that imaging next day after injection might increase the imaging contrast. In the case of <sup>99m</sup>Tc-labeled variants, there was an increase only in tumor-to-blood ratio at the later time point (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). The possible reason for this could be the residualizing nature of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> label, which was then retained in normal tissues after internalization as efficiently as in tumor. Accordingly, the clearance of activity from normal tissues was as slow as from tumors, and the contrast did not increase with time. Thus, the imaging at the day of injection would be optimal for [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3. This matches well with the 6&#8201;h physical half-life of <sup>99m</sup>Tc.<fig id="Fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Binding specificity of [<sup>99m</sup>Tc]Tc-labeled G3 variants to SKOV3 (<bold>A</bold>), BT474 (<bold>B</bold>) and DU145 (<bold>C</bold>) HER2-expressing cell lines <italic toggle="yes">in vitro</italic>. Radiolabeled compounds were added at 1&#8201;nM concentration; 100-fold molar excess of the corresponding non-labeled G3 variant was added for blocking of HER2 receptors. Data are presented as mean from three samples&#8201;&#177;&#8201;standard deviation (SD).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e2662" position="float" orientation="portrait" xlink:href="41598_2019_45795_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Cellular processing of <sup>99m</sup>Tc-labeled G3 variants during continuous incubation with HER2-expressing SKOV3 cells over 24&#8201;h. Data are presented as mean from three samples&#8201;&#177;&#8201;SD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e2674" position="float" orientation="portrait" xlink:href="41598_2019_45795_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Specificity of HER2-targeting by <sup>99m</sup>Tc-labeled G3 variants <italic toggle="yes">in vivo</italic>. Tumor uptake in BALB/C nu/nu mice bearing HER2-positive SKOV3 xenografts was compared to the uptake in mice bearing HER2-negative Ramos xenografts for each variant. Data is presented as individual data points from four mice per group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e2689" position="float" orientation="portrait" xlink:href="41598_2019_45795_Fig4_HTML.jpg"/></fig></p><p id="Par20">Gamma camera imaging confirmed the <italic toggle="yes">ex vivo</italic> measurements data (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>) showing that [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 provided higher tumor-to-background contrast in general and tumor-to-liver in particular.<fig id="Fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Gamma-camera imaging of BALB/C nu/nu mice bearing SKOV3 xenografts injected with <sup>99m</sup>Tc-labeled G3 variants (3.2&#8201;&#956;g, 8 MBq) at 4&#8201;h pi. Contours were derived from a digital photograph and superimposed over images to facilitate interpretation. Arrows are pointing at liver (L), kidneys (K) and tumor (T).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d29e2719" position="float" orientation="portrait" xlink:href="41598_2019_45795_Fig5_HTML.jpg"/></fig></p><p id="Par21">The fact that physicochemical properties of a radionuclide/chelator complex have a strong influence on biodistribution of radiolabeled peptides is well known<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Apparently, an introduction of a chelator and a radionuclide influences charge and lipophilicity of a peptide, which in turn modifies off-target interactions. This affects the predominant excretion pathway, off-target binding to normal tissues and binding to blood proteins resulting in slowing blood clearance rate. Although scaffold proteins are typically bigger than short tumor-targeting peptides, a substantial effect of labeling strategy on biodistribution properties of an ESP affibody molecule has also been shown earlier<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. A noticeable influence of a radionuclide/chelator combination on uptake in normal tissues was observed for another ESP, ADAPT<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Unfortunately, there are no general rules of thumb permitting selection of an optimal label. Probably, the only applicable principle is that the use of more hydrophilic radionuclide/chelator combinations reduces the hepatic uptake of activity<sup><xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref></sup> and binding to plasma proteins<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. However, there are multiple and unexpected exemptions from these rules. For example, the use of a hydrophilic and negatively charged HEHEHE-tag at the C-terminus of affibody molecules for labeling with [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub> resulted in a very substantial decrease of hepatic uptake while the use of equally hydrophilic but positively charged HKHKHK-tag in the same position resulted in a substantial increase of hepatic uptake<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Furthermore, the same tags provided a different effect that was dependent on their position in affibody molecules<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par22">We found in this study that the influence of tag position and composition on biodistribution of DARPin G3 resembled the influence on biodistribution of affibody molecules<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, i.e. hydrophilic tags at N-terminus provided the best imaging properties. However, this observation is different from what was previously found for ADAPTs, where the effect of the HEHEHE tag at N-terminus on biodistribution was minor<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. It has to be noted, though, that the N-terminus of ADAPT6 contains a number of negatively charged amino acids, glutamates and aspartates, which might additionally provide an effect similar to the effect of HEHEHE-tags. Taken together the available data for affibody molecules, ADAPTs and DARPins, we can conclude that the effect of histidine-containing tags depends on local distribution of charge and lipophilicity on a protein&#8217;s surface and is determined by neighbor amino acids in a scaffold protein. However, prediction of this effect for every type of ESP is associated with a high degree of uncertainty. Therefore, a systematic investigation of this effect, as presented here, is necessary to ensure that a tracer with optimal properties is produced.</p></sec><sec id="Sec7" sec-type="conclusion"><title>Conclusion</title><p id="Par23">Both composition and position of histidine-containing tags have a strong influence on biodistribution of anti-HER2 G3 DARPin labeled using [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>. The [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-G3 variant provided the highest tumor-to-lung, tumor-to-liver, tumor-to-bone and tumor-to-muscle ratios, which should improve sensitivity of HER2 imaging in metastases. The labeling strategy for molecular imaging probes based on scaffold proteins should be evaluated to provide not only a stable coupling of a radionuclide, but also the most favorable biodistribution pattern.</p></sec><sec id="Sec8" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec9"><title>Reagents, instruments, statistics</title><p id="Par24">Molecular weight of DARPins was measured by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) on a 6520 Accurate Q-TOF LC/ MS (Agilent). Instant thin-layer chromatography (iTLC) analysis was performed using iTLC silica gel strips (Varian, Lake Forest, CA, USA). The radioactivity distribution along strips was measured using a Cyclone storage phosphor system (Packard) and analyzed by OptiQuant image analysis software. Radio-HPLC analysis was performed using Hitachi Chromaster HPLC system with a radioactivity detector. Vydac RP C18 protein column (300&#8201;A, 3&#8201;&#215;&#8201;150&#8201;mm, 5 &#956;m particle size) was used for analysis. Solvent A was 0.1% trifluoroacetic acid in water, solvent B was 0.1% trifluoroacetic acid in acetonitrile. Flow rate was 1&#8201;mL/min with a gradient of 5% B to 80% B over 20&#8201;minutes. Size-exclusion chromatography was performed using NAP-5 columns (GE Healthcare). Radioactivity was measured using an automated gamma-spectrometer with a NaI(TI) detector (1480 Wizard, Wallac, Finland). Technetium-99m was obtained as pertechnetate by elution of Ultra-TechneKow generator (Mallinckrodt) with sterile 0.9% sodium chloride (Mallinckrodt, The Netherlands). The CRS kits for production of tricarbonyl technetium were purchased from the Center for Radiopharmaceutical Sciences (PSI, Villigen, Switzerland). SKOV3, BT474, DU145 and Ramos cells were purchased from the American Type Culture Collection (ATCC) and were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU/ml penicillin and 100&#8201;&#181;g/ml streptomycin in a humidified incubator with 5% CO<sub>2</sub> at 37&#8201;&#176;C, unless stated otherwise.</p><p id="Par25">Statistical analysis of biological data was performed using GraphPad Prism (Windows GraphPad Software, San Diego, CA, USA) to find any significant differences (p&#8201;&lt;&#8201;0.05), when two sets of data were compared. An unpaired two-tailed t test was used for analysis unless stated otherwise. For comparison of three or more sets of data, a one-way ANOVA test with Bonferroni correction for multiple comparisons was applied (Windows GraphPad Software, San Diego, CA, USA).</p></sec><sec id="Sec10"><title>Protein production</title><p id="Par26">The proteins G3-H<sub>6</sub>, H<sub>6</sub>-G3, (HE)<sub>3</sub>-G3 and G3-(HE)<sub>3</sub> were produced in <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> strain BL21(DE3) (Novagen-EMD Millipore, Madison, WI 53719, USA). The DARPin G3 gene nucleotide sequence was deduced from a DARPin G3 amino acid sequence deposited in PDB (accession number PDB: 2JAB) taking into account the codon usage in highly expressed <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> genes with the help of the freely distributed program DNABuilder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.innovationsinmedicine.org/software/DNABuilder/">http://www.innovationsinmedicine.org/software/DNABuilder/</ext-link>). The gene was assembled by PCR from chemically synthesized oligonucleotides of 50&#8201;bp in length having partially complementary sequences. The additional histidine-containing sequences (tags) were added to the <italic toggle="yes">N</italic>- or <italic toggle="yes">C</italic>-terminus of the DARPin G3 gene by PCR. The amino acid sequence for H<sub>6</sub>-G3 was as follows: MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLN. The amino acid sequence for G3-H<sub>6</sub> was as follows: MDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGSHHHHHH. The amino acid sequence for (HE)<sub>3</sub>-G3 was as follows: MRGSHEHEHEGSDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLN. The amino acid sequence for G3-(HE)<sub>3</sub> was as follows: DLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLLKNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNEDLAEILQKLNGSHEHEHE.</p><p id="Par27">Expression, isolation and purification was performed according to the methodology described earlier<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. The genes for G3-H<sub>6</sub>, H<sub>6</sub>-G3 and (HE)<sub>3</sub>-G3 were directly cloned into the plasmid vector pET39b between the restriction sites <italic toggle="yes">Nde</italic>I and <italic toggle="yes">Hin</italic>dIII. The gene for G3-(HE)<sub>3</sub> was fused to 3&#8242;-terminus of the SUMO<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> gene by overlapping PCR<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. The junction between two genes encoded the following amino acid sequence <italic toggle="yes">(SUMO)-</italic>QIGG&#8224;DLGKK<italic toggle="yes">-(Darpin)</italic>. The 5&#8242;-terminus of SUMO gene was extended by the coding sequence of GHHHHHHGS. The hybrid SUMO-DARPin G3-(HE)<sub>3</sub> gene was cloned into pET39b plasmid vector between restriction sites <italic toggle="yes">Nde</italic>I and <italic toggle="yes">Hin</italic>dIII. Briefly, <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> was grown in the autoinduction ZYM-5052 medium<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> containing 100&#8201;&#956;g/mL kanamycin at 25&#8201;&#176;C. The cells were harvested by centrifugation and resuspended in lysis buffer (200&#8201;mM Tris-HCl, 500&#8201;mM sucrose, 1&#8201;mM EDTA, pH 8.0, 1&#8201;mM PMSF, 60&#8201;&#956;g/mL lysozyme). The suspension was diluted two-fold with distilled water and incubated at room temperature for 30&#8201;min. Cells were broken on ice by a Vibra Cell ultrasonic liquid processor VCX130 (Sonics, USA). After addition of imidazole (30&#8201;mM) and NaCl (500&#8201;mM), the cellular debris were pelleted at 70000&#8201;g at 4&#8201;&#176;C for 30&#8201;min. The supernatant was filtered through a 0.22 &#956;m membrane and applied on a HisTrap HP (1&#8201;mL) column (GE Healthcare, USA) equilibrated with 20&#8201;mM NaPi, pH 7.5, 500&#8201;mM NaCl, 30&#8201;mM imidazole. The bound proteins were eluted with a linear 30&#8211;500&#8201;mM imidazole gradient. The fractions were analyzed by 15% SDS-PAGE. In the case of DARPin (HE)<sub>3</sub>-G3 the imidazole in the cellular lysate, in the column equilibration and wash buffers was omitted to prevent blocking of protein binding to the Ni-chelating sorbent. The homemade SUMO hydrolase (ULP1)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> was added to the combined fractions containing SUMO-DARPin G3-(HE)<sub>3</sub> at the molar ratio 1:100 (enzyme: substrate). After overnight incubation at 6&#8201;&#176;C, the reaction mixture was diluted three-fold with 20&#8201;mM NaPi, pH 7.5, and applied to a HisTrap HP (1&#8201;mL) column equilibrated with 20&#8201;mM NaPi, pH 7.5, 30&#8201;mM imidazole. The flow-through eluate was collected.</p><p id="Par28">Solutions containing DARPins were diluted with 25&#8201;mM Tris-HCl, pH 8.0 and loaded on a MonoQ 10/100 GL column (GE Healthcare, USA) equilibrated with 25&#8201;mM Tris-HCl, pH 8.0. The bound proteins were eluted with a linear 0&#8211;1&#8201;M NaCl gradient. The fractions containing DARPins were pooled, concentrated with Amicon Ultra-15 centrifugal filter, and sterilized by filtration through 0.22 &#956;m membrane. Protein concentrations were determined by UV spectroscopy using &#949;<sub>280</sub>&#8201;=&#8201;2560&#8201;M<sup>&#8722;1</sup> cm<sup>&#8722;1</sup>.</p></sec><sec id="Sec11"><title>Radiolabeling of G3 variants</title><p id="Par29">Site-specific radiolabeling of histidine tag-containing G3 variants with [[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>]<sup>+</sup> was performed as described earlier by Deyev <italic toggle="yes">et al.</italic><sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Briefly, the eluate (500&#8201;&#956;L) containing ca. 3&#8211;5 GBq of [<sup>99m</sup>Tc]Tc was added to a CRS kit, which was then incubated at 100&#8201;&#176;C for 30&#8201;min. After incubation, 12&#8201;&#956;L from the CRS reaction mixture was added to 40&#8201;&#956;g (2.75 nmol) of a G3 variant in 33&#8201;&#956;L of PBS. The resulting mixture was incubated for 60&#8201;min at 60&#8201;&#176;C. Then, a 5000-fold molar excess of histidine (13.7 &#956;mol, 212&#8201;&#956;L of 10&#8201;mg/mL in PBS) was added to the mixture and further incubated for 15&#8201;min at 60&#8201;&#176;C. Radiolabeled G3 variants were purified using NAP-5 columns pre-equilibrated and eluted with PBS. Radiochemical yield and purity were measured using radio-iTLC in PBS<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The radiolabeled DARPins and the reduced- hydrolyzed technetium (RHT) colloid remained at the application point, while [<sup>99m</sup>Tc]TcO<sub>4</sub><sup>&#8722;</sup>, [[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>]<sup>+</sup> and its complex with histidine migrated with the solvent front. To determine the presence of RHT, iTLC strips were eluted with pyridine:acetic acid:water (10:3:1.5)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. In this system, the RHT colloid stayed at the application point, while radiolabeled DARPins, [<sup>99m</sup>Tc]TcO<sub>4</sub><sup>&#8722;</sup>, [[<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>]<sup>+</sup> and its complex with histidine migrated with the solvent front.</p><p id="Par30">Stability test was performed by incubating the purified radiolabeled proteins with 5000-fold molar excess of histidine in PBS for up to 3&#8201;h at room temperature; control samples were incubated in PBS. Samples were analyzed by radio-iTLC analysis in PBS<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p></sec><sec id="Sec12"><title><italic toggle="yes">In vitro</italic> studies</title><p id="Par31">The <italic toggle="yes">in vitro</italic> studies were performed as described previously<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Cells (ca. 1&#8201;&#215;&#8201;10<sup>6</sup> cells/ dish) were seeded one or two days before the experiment, three dishes per group.</p><p id="Par32">Binding specificity of <sup>99m</sup>Tc-labeled G3 variants to HER2 was evaluated using HER2-expressing SKOV3, BT474 and DU145 cells. To saturate HER2 receptors, a 100-fold excess of non-labeled G3 variant (100&#8201;nM) was added to the control group of cells, medium only was added to the second group. After 30&#8201;min, <sup>99m</sup>Tc-labeled G3 variants were added to both groups at 1&#8201;nM concentrations. After incubation for 1&#8201;h at 37&#8201;&#176;C, the cell medium was collected, cells were washed with 1&#8201;mL of fresh medium and 1&#8201;mL of 1&#8201;M NaOH was added to lyse the cells. The cell lysate was collected after 30&#8201;min of incubation with NaOH. The radioactivity in each fraction was measured to calculate the percent of cell-bound radioactivity, which was normalized to the maximum uptake value in each dataset.</p></sec><sec id="Sec13"><title>Affinity measurement using LigandTracer</title><p id="Par33">The binding kinetics of <sup>99m</sup>Tc-labeled G3 variants to living SKOV3 cells was measured using LigandTracer (Ridgeview Instruments AB, V&#228;nge, Sweden), as described earlier<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Kinetics was recorded at room temperature in real time. Increasing concentrations of radiolabeled G3 variants (0.5 and 2&#8201;nM) were added to cells followed by replacement of media and measurements of retention in the dissociation phase. The TraceDrawer Software (Ridgeview Instruments AB, V&#228;nge, Sweden) was used to calculate the dissociation constants based on association and dissociation rates.</p><p id="Par34">Cellular processing of <sup>99m</sup>Tc-labeled G3 variants by SKOV3 cells was studied during continuous incubation by an acid-wash method<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Radiolabeled DARPins (1&#8201;nM) were added to cells and incubated at 37&#8201;&#176;C in a humidified incubator. At 1, 2, 4, 6 and 24&#8201;h post-addition, the media was collected from one set of dishes and cells were washed once with serum-free media (1&#8201;mL). To collect the membrane-bound DARPins, the cells were treated with 0.2&#8201;M glycine buffer containing 4&#8201;M urea, pH 2.0 (1&#8201;mL) on ice for 5&#8201;min, the buffer was collected, and the cells were washed once with the same buffer (1&#8201;mL). To collect the internalized DARPins, the cells were treated with 1&#8201;M NaOH (1&#8201;mL) for 30&#8201;min. The activity in every fraction was measured. The activity in the acid fractions was considered as bound to cell membrane, in the alkaline fractions- as internalized. The data was normalized to the maximum value of cell-bound activity in each dataset.</p></sec><sec id="Sec14"><title>Animal studies</title><p id="Par35">Animal studies were performed according to national legislation on laboratory animal protection and were approved by the Ethical Committee for Animal Research in Uppsala. For tumor implantation, 10<sup>7</sup> of HER2-expressing SKOV3 cells or 5&#8201;&#215;&#8201;10<sup>6</sup> of HER2-negative Ramos cells in 100&#8201;&#181;L of media were subcutaneously injected in the right hind leg of female BALB/c nu/nu mice. The experiments were performed three weeks after implantation. The average animal weight was 18&#8201;&#177;&#8201;1&#8201;g in the SKOV3 groups, 18&#8201;&#177;&#8201;1&#8201;g in the Ramos group. The average tumor weight was 0.06&#8201;&#177;&#8201;0.02&#8201;g for SKOV3 xenografts and 0.2&#8201;&#177;&#8201;0.1&#8201;g for Ramos xenografts. For biodistribution studies, mice were intravenously (i.v.) injected with <sup>99m</sup>Tc-labeled G3 variant (0.22 nmol, 3.2&#8201;&#956;g) in 100&#8201;&#956;L of 1% BSA in PBS/mouse (30&#8201;kBq for <sup>99m</sup>Tc-labeled DARPins for 4&#8201;h groups and 320&#8201;kBq for 24&#8201;h groups). The injected amount of protein was adjusted to by a corresponding non-labeled G3 variant. At 4 and 24&#8201;h post-injection (pi) mice were anesthetized by an intraperitoneal injection of ketamine and xylazine solution and sacrificed by heart puncture. Blood was collected with a heparinized syringe, organs were collected, weighed and activity was measured using a gamma spectrometer. The percent of injected dose per gram of sample (%ID/g) was calculated, except for gastrointestinal tract and carcass where %ID per whole sample was calculated.</p><p id="Par36">For imaging mice bearing SKOV3 xenografts were injected with <sup>99m</sup>Tc-labeled G3 variants (3.2&#8201;&#181;g, 8 MBq) in 100&#8201;&#956;L of 1% BSA in PBS/mouse and sacrificed by CO<sub>2</sub> inhalation at 4&#8201;h pi. The imaging was performed using an Infinia gamma-camera (GE Healthcare) equipped with a low-energy high resolution collimator. Static images (30&#8201;min) were obtained in a 256&#8201;&#215;&#8201;256 matrix.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2019_45795_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-019-45795-8.</p></sec><ack><title>Acknowledgements</title><p>This research was financially supported by grants from the Swedish Cancer Society [grants CAN 2018/436 and 2017/425], Swedish Research Council [grants 2015-02353 and 2015-02509], the Swedish Agency for Innovation VINNOVA (grant 2016-04060), RFBR grants 17-00-00122 (komfi), 18-04-00365 &#1040;, 18-29-08030 mk in the part of protein engineering and purification and the State contract of Russian Federation &#8470; 14.N08.11.0163 and by Tomsk Polytechnic University CE Program.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>A.V.- participation in the study design, labeling chemistry development, <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies, data treatment and interpretation, drafting of the first version of the manuscript; A.S., E.K.-production and purification of the DARPins; R.G., J.L. - biochemical and biophysical characterization of non-labeled DARPins; M.S. - planning and performing <italic toggle="yes">in vivo</italic> imaging study; J.G., O.B., A.O. - participation in planning and performing <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies, data treatment and interpretation, V.C.-data interpretation and critical revision of the text, enhancing intellectual content in the aspects of potential clinical translation; V.T.- participation in the study design, labeling chemistry development, <italic toggle="yes">in vivo</italic> studies, data treatment and interpretation, coordinating work at Uppsala site; S.D. -participation in molecular design of the tracers, supervising production and purification of the DARPins, and coordination of the project. All co-authors revised the manuscript and approved the final variant.</p></notes><notes notes-type="COI-statement"><title>Competing Interests</title><p id="Par37">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arteaga</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Treatment of HER2-positive breast cancer: current status and future perspectives</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2011</year><volume>9</volume><fpage>16</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.177</pub-id><pub-id pub-id-type="pmid">22124364</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>ToGA trial investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title><source>Lancet.</source><year>2010</year><volume>376</volume><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="pmid">20728210</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seol</surname><given-names>H</given-names></name><etal/></person-group><article-title>Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance</article-title><source>Mod. Pathol.</source><year>2012</year><volume>25</volume><fpage>938</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.36</pub-id><pub-id pub-id-type="pmid">22388760</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gingras</surname><given-names>I</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G</given-names></name><name name-style="western"><surname>de Azambuja</surname><given-names>E</given-names></name><name name-style="western"><surname>Piccart-Gebhart</surname><given-names>M</given-names></name></person-group><article-title>HER2-positive breast cancer is lost in translation: time for patient-centered research</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>669</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.96</pub-id><pub-id pub-id-type="pmid">28762384</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behr</surname><given-names>TM</given-names></name><name name-style="western"><surname>B&#233;h&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>W&#246;rmann</surname><given-names>B</given-names></name></person-group><article-title>Trastuzumab and breast cancer</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>345</volume><fpage>995</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1056/NEJM200109273451312</pub-id><pub-id pub-id-type="pmid">11575295</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebhart</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial</article-title><source>Ann. Oncol.</source><year>2016</year><volume>27</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv577</pub-id><pub-id pub-id-type="pmid">26598545</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>AM</given-names></name></person-group><article-title>Engineered antibodies for molecular imaging of cancer</article-title><source>Methods.</source><year>2014</year><volume>65</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2013.09.015</pub-id><pub-id pub-id-type="pmid">24091005</pub-id><pub-id pub-id-type="pmcid">PMC3947235</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hori</surname><given-names>K</given-names></name></person-group><article-title>Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review</article-title><source>J. Control. Release.</source><year>2000</year><volume>65</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00248-5</pub-id><pub-id pub-id-type="pmid">10699287</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name></person-group><article-title>Imaging of HER-2 overexpression in tumors for guiding therapy</article-title><source>Curr. Pharm. Des.</source><year>2008</year><volume>14</volume><fpage>2999</fpage><lpage>3019</lpage><pub-id pub-id-type="doi">10.2174/138161208786404290</pub-id><pub-id pub-id-type="pmid">18991715</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krasniqi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Same-day imaging using small proteins: clinical experience and translational prospects in oncology</article-title><source>J. Nucl. Med.</source><year>2018</year><volume>59</volume><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.2967/jnumed.117.199901</pub-id><pub-id pub-id-type="pmid">29545374</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedford</surname><given-names>R</given-names></name><etal/></person-group><article-title>Alternative reagents to antibodies in imaging applications</article-title><source>Biophys. Rev.</source><year>2017</year><volume>9</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1007/s12551-017-0278-2</pub-id><pub-id pub-id-type="pmid">28752365</pub-id><pub-id pub-id-type="pmcid">PMC5578921</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Levi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name></person-group><article-title>Protein scaffold-based molecular probes for cancer molecular imaging</article-title><source>Amino Acids.</source><year>2001</year><volume>41</volume><fpage>1037</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1007/s00726-010-0503-9</pub-id><pub-id pub-id-type="pmcid">PMC2914822</pub-id><pub-id pub-id-type="pmid">20174842</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pl&#252;ckthun</surname><given-names>A</given-names></name></person-group><article-title>Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2015</year><volume>55</volume><fpage>489</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010611-134654</pub-id><pub-id pub-id-type="pmid">25562645</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Forrer</surname><given-names>P</given-names></name><name name-style="western"><surname>Pl&#252;ckthun</surname><given-names>A</given-names></name></person-group><article-title>Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display</article-title><source>J. Mol. Biol.</source><year>2008</year><volume>382</volume><fpage>1211</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.07.085</pub-id><pub-id pub-id-type="pmid">18706916</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahnd</surname><given-names>C</given-names></name><etal/></person-group><article-title>A designed ankyrin repeat protein evolved to picomolar affinity to Her2</article-title><source>J. Mol. Biol.</source><year>2007</year><volume>369</volume><fpage>1015</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.03.028</pub-id><pub-id pub-id-type="pmid">17466328</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vorobyeva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors</article-title><source>Contrast Media Mol. Imaging.</source><year>2018</year><volume>2018</volume><fpage>6930425</fpage><pub-id pub-id-type="doi">10.1155/2018/6930425</pub-id><pub-id pub-id-type="pmid">29977173</pub-id><pub-id pub-id-type="pmcid">PMC6011117</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahlgren</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules</article-title><source>Bioconjug. Chem.</source><year>2008</year><volume>19</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1021/bc700307y</pub-id><pub-id pub-id-type="pmid">18163536</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahlgren</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine</article-title><source>J. Nucl. Med.</source><year>2009</year><volume>50</volume><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.2967/jnumed.108.056929</pub-id><pub-id pub-id-type="pmid">19372467</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>R</given-names></name><etal/></person-group><article-title>Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging</article-title><source>Eur. J. Nucl. Med. Mol. Imaging.</source><year>2015</year><volume>42</volume><fpage>288</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1007/s00259-014-2940-2</pub-id><pub-id pub-id-type="pmid">25391547</pub-id><pub-id pub-id-type="pmcid">PMC4315530</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name><name name-style="western"><surname>Orlova</surname><given-names>A</given-names></name><name name-style="western"><surname>Lundqvist</surname><given-names>H</given-names></name></person-group><article-title>Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides</article-title><source>Curr. Med. Chem.</source><year>2003</year><volume>2010</volume><fpage>2447</fpage><lpage>2460</lpage><pub-id pub-id-type="doi">10.2174/0929867033456666</pub-id><pub-id pub-id-type="pmid">14529484</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reubi</surname><given-names>JC</given-names></name></person-group><article-title>Peptide receptors as molecular targets for cancer diagnosis and therapy</article-title><source>Endocr. Rev.</source><year>2003</year><volume>24</volume><fpage>389</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1210/er.2002-0007</pub-id><pub-id pub-id-type="pmid">12920149</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deyev</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Comparative evaluation of two DARPin variants: effect of affinity, size and label on tumor targeting properties</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>995</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00922</pub-id><pub-id pub-id-type="pmid">30608701</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vorobyeva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2</article-title><source>Int. J. Oncol.</source><year>2019</year><volume>54</volume><fpage>1209</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">30968147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2019.4712</pub-id><pub-id pub-id-type="pmcid">PMC6411343</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name><etal/></person-group><article-title>HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99(m)Tc(CO)<sub>3</sub>](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation</article-title><source>Bioconjug. Chem.</source><year>2010</year><volume>21</volume><fpage>2013</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1021/bc1002357</pub-id><pub-id pub-id-type="pmid">20964447</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofstr&#246;m</surname><given-names>C</given-names></name><etal/></person-group><article-title>HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>4966</fpage><lpage>4974</lpage><pub-id pub-id-type="doi">10.1021/jm400218y</pub-id><pub-id pub-id-type="pmid">23692562</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Influence of histidine-containing tags on the biodistribution of ADAPT scaffold proteins</article-title><source>Bioconjug. Chem.</source><year>2016</year><volume>27</volume><fpage>716</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00677</pub-id><pub-id pub-id-type="pmid">26781756</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name><name name-style="western"><surname>Stone-Elander</surname><given-names>S</given-names></name></person-group><article-title>Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods</article-title><source>Biochim. Biophys. Acta.</source><year>1800</year><volume>487&#8211;510</volume><fpage>2010</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbagen.2010.02.002</pub-id><pub-id pub-id-type="pmid">20153401</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deri</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zeglis</surname><given-names>BM</given-names></name><name name-style="western"><surname>Francesconi</surname><given-names>LC</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></name></person-group><article-title>PET PET imaging with <sup>89</sup>Zr: from radiochemistry to the clinic</article-title><source>Nucl. Med. Biol.</source><year>2013</year><volume>40</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2012.08.004</pub-id><pub-id pub-id-type="pmid">22998840</pub-id><pub-id pub-id-type="pmcid">PMC3517725</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Ni</surname><given-names>D</given-names></name><name name-style="western"><surname>Ehlerding</surname><given-names>EB</given-names></name><name name-style="western"><surname>Luo</surname><given-names>QY</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name></person-group><article-title>PET Imaging of receptor tyrosine kinases in cancer</article-title><source>Mol. Cancer. Ther.</source><year>2018</year><volume>17</volume><fpage>1625</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0087</pub-id><pub-id pub-id-type="pmid">30068751</pub-id><pub-id pub-id-type="pmcid">PMC6168319</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>IM</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PJH</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S</given-names></name></person-group><article-title>Clinical Applications of Radiolabeled Peptides for PET</article-title><source>Semin. Nucl. Med.</source><year>2017</year><volume>47</volume><fpage>493</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2017.05.007</pub-id><pub-id pub-id-type="pmid">28826523</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niimi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nanasato</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>H</given-names></name></person-group><article-title>Evaluation of cadmium-zinc-telluride detector-based single-photon emission computed tomography for nuclear cardiology: a comparison with conventional anger single-photon emission computed tomography</article-title><source>Nucl. Med. Mol. Imaging.</source><year>2017</year><volume>51</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1007/s13139-017-0474-9</pub-id><pub-id pub-id-type="pmid">29242727</pub-id><pub-id pub-id-type="pmcid">PMC5721085</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name><name name-style="western"><surname>Orlova</surname><given-names>A</given-names></name></person-group><article-title>Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets</article-title><source>Curr. Med. Chem.</source><year>2010</year><volume>17</volume><fpage>2636</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.2174/092986710791859397</pub-id><pub-id pub-id-type="pmid">20491631</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decristoforo</surname><given-names>C</given-names></name><name name-style="western"><surname>Mather</surname><given-names>SJ</given-names></name></person-group><article-title>The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides</article-title><source>Q. J. Nucl. Med.</source><year>2002</year><volume>46</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">12134136</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Optimized molecular design of ADAPT-based HER2-imaging probes labeled with 111In and 68Ga</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>2674</fpage><lpage>2683</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00204</pub-id><pub-id pub-id-type="pmid">29865791</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trejtnar</surname><given-names>F</given-names></name><name name-style="western"><surname>Laznicek</surname><given-names>M</given-names></name><name name-style="western"><surname>Laznickova</surname><given-names>A</given-names></name><name name-style="western"><surname>Mather</surname><given-names>SJ</given-names></name></person-group><article-title>Pharmacokinetics and renal handling of 99mTc-labeled peptides</article-title><source>J. Nucl. Med.</source><year>2000</year><volume>41</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">10647621</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rusckowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Qu</surname><given-names>T</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Ley</surname><given-names>A</given-names></name><name name-style="western"><surname>Hnatowich</surname><given-names>DJ</given-names></name></person-group><article-title>A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods</article-title><source>J. Nucl. Med.</source><year>2001</year><volume>42</volume><fpage>1870</fpage><lpage>1877</lpage><pub-id pub-id-type="pmid">11752087</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseinimehr</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Tolmachev</surname><given-names>V</given-names></name><name name-style="western"><surname>Orlova</surname><given-names>A</given-names></name></person-group><article-title>Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design</article-title><source>Drug Discov. Today.</source><year>2012</year><volume>17</volume><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2012.07.002</pub-id><pub-id pub-id-type="pmid">22781499</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#225;zn&#237;cek</surname><given-names>M</given-names></name><name name-style="western"><surname>L&#225;zn&#237;ckov&#225;</surname><given-names>A</given-names></name></person-group><article-title>The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs</article-title><source>J. Pharm. Biomed. Anal.</source><year>1995</year><volume>13</volume><fpage>823</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/0731-7085(95)01504-E</pub-id><pub-id pub-id-type="pmid">8562605</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decristoforo</surname><given-names>C</given-names></name><name name-style="western"><surname>Mather</surname><given-names>SJ</given-names></name></person-group><article-title>99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution</article-title><source>Nucl. Med. Biol.</source><year>1999</year><volume>126</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/S0969-8051(98)00118-8</pub-id><pub-id pub-id-type="pmid">10382842</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malakhov</surname><given-names>MP</given-names></name><etal/></person-group><article-title>SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins</article-title><source>J. Struct. Funct. Genomics.</source><year>2004</year><volume>5</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1023/B:JSFG.0000029237.70316.52</pub-id><pub-id pub-id-type="pmid">15263846</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heckman</surname><given-names>KL</given-names></name><name name-style="western"><surname>Pease</surname><given-names>LR</given-names></name></person-group><article-title>Gene splicing and mutagenesis by PCR-driven overlap extension</article-title><source>Nat. Protoc.</source><year>2007</year><volume>2</volume><fpage>924</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.132</pub-id><pub-id pub-id-type="pmid">17446874</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Studier</surname><given-names>FW</given-names></name></person-group><article-title>Protein production by auto-induction in high density shaking cultures</article-title><source>Protein Expression Purif.</source><year>2019</year><volume>41</volume><fpage>207</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.01.016</pub-id><pub-id pub-id-type="pmid">15915565</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>